FindTrial
Sign In

An ambispective study of the efficacy and safety of tirofiban and heparin in 30 days after coronary artery bypass grafting combined with coronary endarterectomy

A ambispective study of the efficacy and safety of tirofiban and heparin in 30 days after coronary artery bypass grafting combined with coronary endarterectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055661
Enrollment
Unknown
Registered
2022-01-16
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

tirofiban group:
heparin group:

Sponsors

Capital Medical University Affiliated Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. During the coronary artery bypass grafting operation, the anastomosis of the graft vessel cannot complete the conventional coronary anastomosis (the coronary intima at the anastomosis is thickened to a lumen diameter < 1 mm, or the intima at the distal end of the coronary anastomosis is thickened to a lumen diameter < 1 mm, or the coronary artery at the anastomosis is stratified due to atherosclerosis) and undergoes coronary endarterectomy (CE); 3. Patients with more than one coronary target vessel undergoing CE surgery and no new Q-wave ECG changes before intravenous administration.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative echocardiography showing ejection fraction = 5 points, serum HBsAg positive, HBeAg positive, HCV-RNA positive, anti-HCV positive patients; 9. Patients with known coagulation dysfunction, abnormal platelet history or thrombocytopenia (preoperative platelet count < 150000 /mm3) before operation; 10. Patients with active internal hemorrhage, intracranial hemorrhage, intracranial tumor, arteriovenous malformation and aneurysm; 11. Bleeding within half a year, including gastrointestinal bleeding or clinically significant urogenital bleeding; 12. History of hemorrhagic or ischemic stroke within half a year.

Design outcomes

Primary

MeasureTime frame
Grading of perioperative bleeding in adult cardiac surgery;thrombolysis in myocardial infarction (TIMI) in 30 days;Incidence rate of major adverse cardiovascular and cerebrovascular events 30 days after operation;—

Secondary

MeasureTime frame
all-cause motality;nonfatal myocardial infarction;nonfatal stroke;—

Countries

China

Contacts

Public ContactYang Yu

Capital Medical University Affiliated Beijing Anzhen Hospital

heartyuyang@hotmail.com+86 13370103520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026